Mexico Women's Health Market Size & Outlook, 2024-2030
Mexico women's health market, 2018-2030 (US$M)
Related Markets
Mexico women’s health market highlights
- The Mexico women’s health market generated a revenue of USD 514.5 million in 2023 and is expected to reach USD 863.6 million by 2030.
- The Mexico market is expected to grow at a CAGR of 7.7% from 2024 to 2030.
- In terms of segment, contraceptives was the largest revenue generating application in 2023.
- Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.
Women’s health market data book summary
| Market revenue in 2023 | USD 514.5 million |
| Market revenue in 2030 | USD 863.6 million |
| Growth rate | 7.7% (CAGR from 2023 to 2030) |
| Largest segment | Contraceptives |
| Fastest growing segment | Endometriosis & Uterine Fibroids |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, Mexico accounted for 1.2% of the global women’s health market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Latin America, Brazil women’s health market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in Latin America and is projected to reach USD 863.6 million by 2030.
Contraceptives was the largest segment with a revenue share of 42.93% in 2024. Horizon Databook has segmented the Mexico women's health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico’s pharmaceutical industry is the second-largest pharmaceutical industry in Latin America. Its growth is primarily due to the local presence of key market players, an increasing number of startups, and rising investments.
For instance, in October 2023, Merck KGaA launched a comprehensive Fertility Benefit program that will offer financial support to its employees and partners for fertility treatments in eight major markets: the UK, Germany, China, India, Mexico, Brazil, Switzerland, and Taiwan.
Women are at a higher risk of reproductive complications in this country. Government initiatives pertaining to reforming women’s health are expected to raise awareness and educate women regarding female reproductive health.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Women's Health Market Scope
Women's Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Mexico Women's Health Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
